Given that the iPSC-based vaccine induces anti-tumor immunity through CD8+ T cell activation, we further explored whether dendritic cells can present antigens derived from iPSC whole cell lysates using mouse bone marrow-derived dendritic cell (BMDC) models (Figure 5A). This evidence concerns the gene CD8A and neoplasm.